Virginia A Triant1, Steven K Grinspoon. 1. aDivision of General Internal Medicine bDivision of Infectious Diseases cProgram in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize and synthesize recent data on the risk of ischemic heart disease (IHD) in HIV-infected individuals. RECENT FINDINGS: Recent studies in the field demonstrate an increasing impact of cardiovascular disease (CVD) on morbidity and mortality in HIV relative to AIDS-related diagnoses. Studies continue to support an approximately 1.5 to two-fold increased risk of IHD conferred by HIV, with specific risk varying by sex and virologic/immunologic status. Risk factors include both traditional CVD risk factors and novel, HIV-specific factors including inflammation and immune activation. Specific antiretroviral therapy (ART) drugs may increase CVD risk, yet the net effect of ART with viral suppression is beneficial with regard to CVD risk. Management of cardiovascular risk and prevention of CVD is complex, because current general population strategies target traditional CVD risk factors only. Extensive investigation is being directed at developing tailored CVD risk prediction algorithms and interventions to reduce CVD risk in HIV. SUMMARY: Increased IHD risk is a significant clinical and public health challenge in HIV. The development and application of HIV-specific interventions to manage CVD risk factors and reduce CVD risk will improve the long-term health of this ageing population.
PURPOSE OF REVIEW: The purpose of this review is to summarize and synthesize recent data on the risk of ischemic heart disease (IHD) in HIV-infected individuals. RECENT FINDINGS: Recent studies in the field demonstrate an increasing impact of cardiovascular disease (CVD) on morbidity and mortality in HIV relative to AIDS-related diagnoses. Studies continue to support an approximately 1.5 to two-fold increased risk of IHD conferred by HIV, with specific risk varying by sex and virologic/immunologic status. Risk factors include both traditional CVD risk factors and novel, HIV-specific factors including inflammation and immune activation. Specific antiretroviral therapy (ART) drugs may increase CVD risk, yet the net effect of ART with viral suppression is beneficial with regard to CVD risk. Management of cardiovascular risk and prevention of CVD is complex, because current general population strategies target traditional CVD risk factors only. Extensive investigation is being directed at developing tailored CVD risk prediction algorithms and interventions to reduce CVD risk in HIV. SUMMARY: Increased IHD risk is a significant clinical and public health challenge in HIV. The development and application of HIV-specific interventions to manage CVD risk factors and reduce CVD risk will improve the long-term health of this ageing population.
Authors: Shahida Shahrir; Hilary A Tindle; Kathleen A McGinnis; David A Fiellin; Joseph Goulet; Kathleen M Akgün; Cynthia L Gibert; Maria C Rodriguez-Barradas; Kristina Crothers Journal: Subst Abus Date: 2015-07-13 Impact factor: 3.716
Authors: Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr Journal: Clin Infect Dis Date: 2009-11-15 Impact factor: 9.079
Authors: Matthew J Feinstein; Ehete Bahiru; Chad Achenbach; Christopher T Longenecker; Priscilla Hsue; Kaku So-Armah; Matthew S Freiberg; Donald M Lloyd-Jones Journal: Am J Cardiol Date: 2015-11-06 Impact factor: 2.778
Authors: Eric Nou; Michael T Lu; Sara E Looby; Kathleen V Fitch; Elli A Kim; Hang Lee; Udo Hoffmann; Steven K Grinspoon; Janet Lo Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren Journal: BMC Med Date: 2016-03-31 Impact factor: 8.775
Authors: Lediya T Cheru; Kathleen V Fitch; Charles F Saylor; Michael Lu; Udo Hoffmann; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Suman Srinivasa; Teressa S Thomas; Meghan N Feldpausch; Gail K Adler; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 5.958
Authors: Ben Alencherry; Geoffrey Erem; Grace Mirembe; Isaac Ssinabulya; Chun-Ho Yun; Chung-Lieh Hung; Mark J Siedner; Marcio Bittencourt; Cissy Kityo; Grace A McComsey; Chris T Longenecker Journal: Open Heart Date: 2019-05-22
Authors: James Brown; Elisha Pickett; Colette Smith; Memory Sachikonye; Lucy Brooks; Tabitha Mahungu; David M Lowe; Sara Madge; Mike Youle; Margaret Johnson; John R Hurst; Timothy D McHugh; Ibrahim Abubakar; Marc Lipman Journal: PLoS One Date: 2020-05-29 Impact factor: 3.240
Authors: James Brown; Christianna Kyriacou; Elisha Pickett; Kelly Edwards; Hemal Joshi; Nafeesah Stewart; Andrew Melville; Margaret Johnson; Jan Flint; Angela Bartley; Alison Rodger; Marc Lipman Journal: BMJ Open Respir Res Date: 2019-10-03
Authors: Colton Leavitt; Neil A Zakai; Paul Auer; Mary Cushman; Ethan M Lange; Emily B Levitan; Nels Olson; Timothy A Thornton; Russell P Tracy; James G Wilson; Leslie A Lange; Alex P Reiner; Laura M Raffield Journal: PLoS One Date: 2020-04-02 Impact factor: 3.240